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Abstract
Background: Serology is often used for the diagnosis of Mycoplasma pneumoniae. It is important
to identify specific antigens that can distinguish between the presence or absence of antibodies
against M. pneumoniae. The two proteins, P116 and P1, are found to be immunogenic. By using
these in ELISA it is possible to identify an immune response against M. pneumoniae in serum
samples.
Results: A recombinant protein derived from the P116 protein and one from the P1 protein were
used in two ELISA tests, rP116-ELISA and rP1-ELISA. Human serum samples from patients with
atypical pneumonia were tested and compared to the results of the complement fixation test.
There was a good agreement between the two tests but the rP1-ELISA showed the best
discrimination between positive and negative samples.
Conclusion: Two ELISA tests based on recombinant proteins have been analysed and compared
to the complement fixation test results. The two ELISA tests were found suitable for use in
serodiagnostics of M. pneumoniae infections. The use of specific antigens eliminates the risk of cross
reaction to an immune response against other bacteria.
Background
Mycoplasma pneumoniae is a human pathogen that colo-
nizes the mucosal surfaces of the respiratory tract [1]. The
pathogen infects the upper and the lower respiratory tract
and is the leading cause of atypical pneumonia in children
and young adults [2]. M. pneumoniae infections are often
seen as epidemics occurring at intervals of 4–7 years. The
patients show flu-like symptoms but characteristically the
infection is chronic in onset and recovery [3].
The lacking cell wall distinguishes Mollicutes from other
eubacteria and due to the lack of cell wall M. pneumoniae
is resistant to penicillin. A specific and early diagnosis is
therefore important in order to select the right treatment.
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The standard methods for diagnosis of M. pneumoniae are
culturing, serology and PCR. Since M. pneumoniae can be
difficult to isolate [4] most of the laboratory diagnoses are
serology tests, such as complement fixation test (CF test)
and different enzyme-linked immunoabsorbent assays
(ELISA) [5]. PCR has also been used for the detection of
M. pneumoniae [6-8]. The CF test has a limited value pro-
ducing inconclusive results, because it also measures anti-
bodies deriving from earlier infections [9], and the
glycolipid antigen which is not M. pneumoniae specific
cross reacts with antigens of different origin such as other
microorganism and body tissues [10-12]. Since serology
often is used for the diagnosis of M. pneumoniae infec-
tions, it is important to identify specific antigens, which
can distinguish between previous and current infection
and determine the presence or absence of antibodies.
Such antigens can then be used in ELISA with either IgM,
IgG or IgA. Investigations have shown that young people
tend to have a higher level of IgM antibodies in acute
infections, while adults often lack the formation of IgM
[9,13].
Two proteins, the P1 protein and a 116 kDa protein have
been characterized as immunogenic [14,15]. These pro-
teins were used in serodiagnostic ELISA tests, the P1 pro-
tein as enriched antigen or in ether-extracted antigen
preparations [16] and the P116 protein as a recombinant
protein [17]. In the present study these antigens were
tested individually by ELISA on parallel serum samples
from patients with atypical pneumonia.
Results
Complement fixation test
The CF test is often used as the gold standard when testing
blood samples for M. pneumoniae antibodies. The CF test
was used to test 125 patients which all suffered from lower
respiratory disease and/or pneumonia. The test results
showed that 55 of the 125 (44%) patients were seroposi-
tive and 70 were seronegative. All the positive patients
showed a fourfold titer rise or a titer of 128 or higher.
Western blotting
Blood samples from seven of the 125 patients were
selected based on the CF results for Western blotting with
whole cell proteins. Five of these were positive in the CF
test (nos. 1, 2, 4, 5 and 6) and two were negative (nos. 3
and 7). Three blood samples were obtained from each of
the patients. The human serum samples were investigated
for IgM, IgA and IgG antibodies to M. pneumoniae (Figure
1A,1B,1C). In immunoblotting a patient was considered
as positive if an increase in band intensity between serum
samples was observed and negative if either no bands
were visible or the bands were equally stained with all
three serum samples.
With IgM a positive reaction was seen with a 170 kDa pro-
tein in two of the CF test positive samples (nos. 4 and 6).
IgA positive reaction was seen with the 170 kDa protein
with all of the five CF test positive, and two of the CF test
positive samples showed a positive reaction with a 116
kDa protein (nos. 5 and 6). The IgG response was the
strongest of the responses. The IgG seropositive human
sera reacted strongly with the two antigens of 170 kDa and
116 kDa. The immunogenicity and size of the two pro-
teins indicated that these were the P1 protein (170 kDa)
[15,18,19] and the P116 protein (116 kDa) [14]. In addi-
tion, some of the human sera also reacted with M. pneu-
moniae proteins of 137, 85, 72, 66, and 55 kDa (Figure 1).
With IgG an increase in band intensity of the P1 protein
and the P116 protein was observed in all five CF test pos-
itive serum samples. The two CF negative patients were
also negative in immunoblotting since no change in band
intensity was seen. The presence of IgG antibodies in the
negative samples might be due to a prior infection with M.
pneumoniae. Several groups have shown that the most
immunogenic proteins are the P1 and P116 proteins
[14,15,18,19]. This was also found in this study (Figure
1). It was therefore decided to test the 125 atypical pneu-
monia patient sera with two ELISA tests using the P1 pro-
tein and P116 protein as antigens respectively.
rP1-ELISA
To determine the frequency of antibodies to rP1 and to
quantify the response, the purified recombinant rP1 was
used in an automated ELISA called rP1-ELISA. The antigen
concentration was optimized to get the best discrimina-
tion between positive and negative samples. A concentra-
tion of 2 µg/ml gave the best discrimination between the
high and low OD values. The rP1-ELISA test was used to
test the 125 atypical pneumonia patients for both IgM,
IgA and IgG antibodies against the P1 protein (Table 1
and Figure 2, CF positive serum samples are shown in
red). A patient was considered positive for an M. pneumo-
niae infection if the OD value changed with more than
0.4. Thirty six (29%) of the individuals had raised IgM
antibodies against the P1 protein and 89 (71%) were
seronegative. Twenty two (18%) were IgA seropositive
and 103 (82%) were seronegative. When looking at the
IgG response 57 (46%) were seropositive and 68 (54%)
were determined negative. The results are shown in Table
1 and Figure 2.
rP116-ELISA
Similarly, the frequency of antibodies to rP116 was quan-
tified. The purified rP116 was used in the rP116-ELISA.
Here the optimization of the antigen concentration
showed that a concentration of 2.5 µg/ml gave the best
discrimination between the high and low OD values. The
serum samples were investigated for both IgM, IgA andBMC Microbiology 2004, 4 http://www.biomedcentral.com/1471-2180/4/7
Page 3 of 10
(page number not for citation purposes)
Immunoblotting of M. pneumoniae whole cells using human serum samples from a typical pneumonia patients Figure 1
Immunoblotting of M. pneumoniae whole cells using human serum samples from a typical pneumonia patients. 
Three blood samples were collected from each patient (nos. 1–7) with an interval of about 14 days. The human serum samples 
were analysed for A) anti-IgM, B) anti-IgA and C) anti-IgG antibodies to M. pneumoniae. The P1 and P116 proteins are marked. 
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IgG antibodies against the P116 protein. The rP116-ELISA
result is shown in Table 1 and Figure 2. As for the rP1-
ELISA a patient was considered positive for an M. pneumo-
niae infection if a change in OD value with more than OD
0.4 was seen. Thirty two (26%) patients were tested posi-
tive for IgM antibodies and 93 (74%) were tested seroneg-
ative. When looking at the IgA response 29 (23%) were
tested seropositive and 96 (77%) were tested seronega-
tive. Sixty nine (55%) of the patients were IgG seroposi-
tive and 56 (45%) were seronegative.
Most of the IgM ELISA positive individuals in both ELISA
tests had a distinct rise in antibody level between the first
blood sample (acute-phase serum) and the second blood
sample. Many of the patients' IgM antibody level
decreased from the second to the third blood sample. This
picture was even more prevalent with the IgA positive
patients where an increase in antibody response was seen
between the acute-phase and the second blood sample
and after that the IgA response decreased markedly. The
IgG response of the seropositive patients was different
from the IgM and IgA responses since the IgG antibody
level kept at a constant level from the second to the third
serum sample after increase between the first and second
serum sample.
Comparison of the results from the three tests
In all three tests 49 were found positive, 10 were positive
in two tests, 14 were positive in one test and 52 were neg-
ative (Table 2). Eleven of the 14 were only positive with
the IgG rP116-ELISA, two were only positive by the CF test
and one with IgG rP1-ELISA.
Age dependence
The patients were divided into three age groups (16–30
years, 31–50 years and 51–83 years). The results showed
that a mycoplasma etiology of atypical pneumonia was
related to age (Table 3). Of the 125 patients most of those
found positive with both IgG and IgM were between 16
and 30 years old. The percentage of positives in this age
group was 55% for IgM and 71% for IgG in the rP1-ELISA
(Table 3). In comparison no IgM positive samples were
found in either of the two ELISA tests in the age group 51–
83 and only a few IgG positive samples were found in this
group. The same picture was seen in the CF test where
77% were positive in the group 16–30 years and only 8%
were positive in the group 51–83 years.
Discussion
Respiratory disease due to M. pneumoniae can be con-
firmed with serological methods of which the CF test is
the most widely used. So far, no commercial ELISA test
using recombinant proteins or synthetic peptides of M.
pneumoniae proteins has been developed.
We compared three different antigens for detecting anti-
bodies against M. pneumoniae, the rP116-ELISA, the rP1-
ELISA and the CF test. Of the 125 patients tested, 55
showed a fourfold rise in antibody titer/ high titer, when
tested by the CF test. Fiftyone of these were identified as
positive with anti-human IgG in rP1-ELISA. Similarly, 52
were tested positive with rP116-ELISA. Of the 70 negative
CF test samples six were positive with rP1-ELISA whereas
17 were positive in the rP116-ELISA. When comparing
patient serum samples found positive only by one test, the
IgG rP116-ELISA showed positive reaction with 11
patients while IgG rP1-ELISA tested one positive and the
CF test tested 2 positive (Table 2). Therefore the CF test
and the rP1-ELISA showed the best agreement. The CF test
measured antibodies to M. pneumoniae glycolipid antigen
and can thus react with antigens of different origins
[10,11,20]. However, this seems not to be a problem in
the present study where serum samples from atypical
pneumonia patients were tested. The antigen used in the
rP116-ELISA and the rP1-ELISA were recombinant pro-
teins, which means that the two tests measured antibodies
specific to the P116 or the P1 protein. The advantage of
using a purified recombinant protein in serodiagnosis
rather than the complex fractions used in the CF test is
improved specificity. With the CF test the specific antigens
are not known and cross-reactivity has been observed with
the closely related Mycoplasma genitalium [20]. However,
no reaction to the rP1 and rP116 proteins was observed
with an antibody raised against M. genitalium and the rP1
and rP116 proteins [21].
Table 1: Positive ELISA results with atypical pneumonia patients. () indicates patients found positive in both CF test and the respective 
ELISA test. The CF test does not measure IgA antibodies
Test IgG IgM IgA
CF test 55
rP116-ELISA 69 (52) 32 (25) 29
rP1-ELISA 57 (51) 36 (32) 22BMC Microbiology 2004, 4 http://www.biomedcentral.com/1471-2180/4/7
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ELISA results obtained with rP116-ELISA and rP1-ELISA Figure 2
ELISA results obtained with rP116-ELISA and rP1-ELISA. The A) IgM, B) IgA and C) IgG levels are illustrated. The 
patients tested positive by the CF test are indicated by red color and the CF negative are marked by black.
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The CF test detects both IgG and IgM antibodies [5] while
the two ELISA tests were designed to detect one of the
antibodies. The ELISA tests seems to detect smaller
amounts of IgG or IgM and they may therefore be more
sensitive.
The blood samples were obtained from patients with
atypical pneumonia. Earlier investigations have shown
that during a M. pneumoniae epidemic 20–38% of patients
with respiratory tract infection have a serologically con-
firmed M. pneumoniae infection [22]. In this study 47%
were positive in at least two of the tests.
Whether an ELISA test should be based on the IgM, IgA or
IgG response depends on the age of the patients. An IgM
response can be minimal or undetectable in case of adult
reinfection with M. pneumoniae. In addition, the samples
should be taken at the right time after infection. It was
proposed that an ELISA test based on IgM for children and
young adults and a test based on IgG for adults are the
best ways to detect M. pneumoniae infections [23]. This is
confirmed in the present study were younger patients had
a higher IgM level while the older patients showed higher
IgG levels (Figure 3 and 4). The use of the IgA response did
not provide additional information since the number of
positive samples was lower than the number found to be
IgG and/or IgM positive with the rP1-ELISA and the
rP116-ELISA. The antibiotic treatment with doxycycline (a
tetracycline) and roxithromycin (a derivate of erythromy-
cin) which was started immediately after the collection of
the first blood sample, might be the reason why the IgA
OD level was kept in the low range (OD 0–0.4) and why
the IgA OD titre was markedly lowered after the second
blood sample was collected. Anti-M. pneumoniae IgG
remains elevated for at least a year following infection. A
high antibody titre in a single serum sample may suggest
current infection or persistence after a recent or past infec-
tion and thus it is not diagnostic. The ELISA tests are of
best value in demonstrating an increase in antibody level
[24] and it is necessary to collect a second and maybe a
third blood sample to confirm an acute infection with M.
pneumoniae [5]. The detection of both IgM and IgG anti-
bodies and the use of more than one serum sample seem
to increase the reliability of diagnosing an M. pneumoniae
infection, and use of the rP1-ELISA test with paired sera
and with both IgG and IgM seems to be the best choice.
The results obtained in the present study indicated that
rP116 could be used as a serodiagnostic reagent, but the
rP1-ELISA test seems to be the best since it differentiates
better between the positive and negative samples (Figure
2). An ELISA test combining the rP1 and rP116 proteins
might give a better test because different patients could
react more strongly to one antigen than the other.
If a PCR test is used for the detection of M. pneumoniae and
the results turned out to be negative, serology with a test
as rP1-ELISA could be used to decide if a patient is
infected by M. pneumoniae or not.
Using a specific test for measuring antibodies against M.
pneumoniae is relevant because otherwise it can be difficult
to obtain a correct diagnosis of atypical pneumonia. It is
Table 2: Comparison of the three tests. The CF test results were compared with the IgG ELISA tests. Of the 14 tested positive by one 
test 11 were only found positive with the IgG rP116-ELISA, two in the CF test and one with the IgG rP1-ELISA
Positive Percent
Positive in all three tests 49 39%
Positive by two tests 10 8%
Positive by one test 14 11%
Negative in all three test 52 42%
Table 3: Age dependence of the immune response to an M. pneumoniae infection. The absolute number of patients with positive serum 
samples is given together with the percentages in () of the total number of patients in the age groups
Positive in rP116-ELISA Positive in rP1-ELISA Positive in CFT
IgM IgG IgM IgG
Age 16–30 12 (39%) 24 (77%) 17 (55%) 22 (74%) 24 (77%)
Age 31–50 20 (29%) 39 (56%) 19 (27%) 33 (47%) 29 (41%)
Age 51–83 0 (0%) 6 (25%) 0 (0%) 2 (8%) 2 (8%)BMC Microbiology 2004, 4 http://www.biomedcentral.com/1471-2180/4/7
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rP1-ELISA results divided into three different age groups Figure 3
rP1-ELISA results divided into three different age groups. A) Age 16–30 years IgG, B) 16–30 years IgM, C) Age 31–50 
years IgG, D) Age 31–50 years IgM, E) Age 51–83 years IgG and F) Age 51–83 years IgM. The patients tested positive by the CF 
test are indicated by red color and the CF negative are marked by black.
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rP116-ELISA results divided into three different age groups Figure 4
rP116-ELISA results divided into three different age groups. A) Age 16–30 years IgG, B) 16–30 years IgM, C) Age 31–
50 years IgG, D) Age 31–50 years IgM, E) Age 51–83 years IgG and F) Age 51–83 years IgM. The patients tested positive by the 
CF test are indicated by red color and the CF negative are marked by black.
rP116-ELISA - IgG
Age: 16-30 year
0
0.5
1
1.5
2
2.5
3
3.5
4
1st 2nd 3rd
Blood sample
A
b
s
o
r
b
a
n
c
e
 
(
O
D
)
rP116-ELISA - IgM
Age: 16-30 year
0
0.5
1
1.5
2
2.5
3
3.5
4
1st 2nd 3rd
Blood sample
A
b
s
o
r
b
a
n
c
e
 
(
O
D
)
rP116-ELISA - IgG
Age: 31-50 year
0
0.5
1
1.5
2
2.5
3
3.5
4
1st 2nd 3rd
Blood sample
A
b
s
o
r
b
a
n
c
e
 
(
O
D
)
rP116-ELISA - IgM
Age: 31-50 year
0
0.5
1
1.5
2
2.5
3
3.5
4
1st 2nd 3rd
Blood sample
A
b
s
o
r
b
a
n
c
e
 
(
O
D
)
rP116-ELISA - IgG
Age: 51-83 year
0
0.5
1
1.5
2
2.5
3
3.5
4
1st 2nd 3rd
Blood sample
A
b
s
o
r
b
a
n
c
e
 
(
O
D
)
rP116-ELISA - IgM
Age: 51-83 year
0
0.5
1
1.5
2
2.5
3
3.5
4
1st 2nd 3rd
Blood sample
A
b
s
o
r
b
a
n
c
e
 
(
O
D
)
A
C
E
B
D
FBMC Microbiology 2004, 4 http://www.biomedcentral.com/1471-2180/4/7
Page 9 of 10
(page number not for citation purposes)
essential to be able to diagnose a M. pneumoniae infection
fast and reliably to give the patient the correct treatment.
An early diagnosis can also warn the medical community
of an impending epidemic of M. pneumoniae pneumonia.
Conclusion
In conclusion the present study showed that the three tests
used can detect antibodies against M. pneumoniae in
patients with atypical pneumoniae. Two of the tests were
based on recombinant proteins, they were both found
suitable for use in serodiagnostics of M. pneumoniae infec-
tion, although the rP1-ELISA test and the CF test showed
the best agreement. An advantage of using specific anti-
gens is that it eliminates the risk of cross reaction to an
immune response against other bacteria.
Methods
Patient sera
Acute and convalescent-phase sera were collected from
patients with atypical pneumonia in Malmø, Sweden in
the period from 1990–93. Two or three blood samples
were obtained from each of the 125 patients, which all
suffered from lower respiratory disease and/or pneumo-
nia. The first blood sample was collected in the acute
phase of the disease. The second and third serum samples
were obtained 14 and 28 days later. The serum samples
were obtained during a suspected outbreak of respiratory
infections caused by M. pneumoniae. The age range of the
patients was from 16 to 83 years. The blood samples were
tested for M. pneumoniae by the use of a complement fixa-
tion test.
Bacterial strain
M. pneumoniae FH (ATCC, MD, USA) was cultured in 100
ml SP-4 medium [25] in TPP tissue culture flasks (Medi-
Cult, Copenhagen, Denmark) and incubated at 37°C for
48 h. An exponential growth phase was indicated by a
color change of the medium from red to orange. The plas-
tic adherent cells were scraped off into phosphate-buff-
ered saline (PBS) and centrifuged at 10,000 × g for 30 min.
The cells were washed in 5 ml PBS and centrifuged at
20,000 × g for 15 min. The pellets were stored at -70°C.
Generation of recombinant proteins
Most of the P116 gene was cloned and used for the pro-
duction of a recombinant protein called rP116. The
recombinant protein was produced as described
previously [26]. A recombinant protein covering a part of
the C-terminal part of the P1 protein called rP1 was sup-
plied by medac, Germany. The two recombinant proteins
were used in the two ELISA tests.
Immunoblotting
Proteins (100 µg) of M. pneumoniae whole cells were dis-
solved in 150 µl SDS sample buffer (62,5 mM, 10% v/v
glycerol, 2.3% v/w SDS, 5% v/v β-mercaptoethanol,
0.05% w/v bromphenol blue), boiled for two min. and
separated by SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) using 10% SDS-polyacrylamide gels with 5%
stacking gel. The gels were transferred to nitrocellulose
membranes (Schleicher & Schull, Dassel, Germany) by
electroblotting. The membrane was blocked for 15 min. at
37°C with blocking buffer (20 mM Tris-base, 150 mM
NaCl, 3% gelatine) except for the molecular weight
marker, which was cut from the membrane and stained
with Amido Schwartz. The membrane was cut into 3 mm
strips and these were incubated with human serum
samples diluted 1:200 in antibody buffer (20 mM Tris-
base, 150 mM NaCl, 3% gelatine, 0.05% Tween-20) for 1
h at 37°C. Bound IgG was detected with Alkaline phos-
phatase (AP)-conjugated goat-antihuman-AP diluted
1:3000. The strips were developed for 10 min. with a
nitroblue tetrazolium (NBT) and 5-bromo-4-chloro-3-
indolyl phosphate p-toluidium (BCIP) solution.
ELISA
The 96 wells maxisorp microtitre ELISA plates (Nunc,
Roskilde, Denmark) were coated with 60 µl per well in
duplicate of the rP116 (2.5 µg/ml) or rP1 (2.0 µg/ ml) in
Carbonate-Coating-Buffer (0.1 M Na2CO3, 15 mM
NaN3)). The plates were incubated over night at 4°C and
blocked in 75 µl blocking buffer (15% fetal calf serum in
PBS with 0.02% SodiumAzid) at 37°C for 1 h. After wash-
ing with PBS + 0.05% Tween-20, 50 µl human sera sam-
ples diluted 1:50 was added to the plates and incubated at
37°C for 1 h. The plates were washed and then incubated
with 50 µl of peroxidase conjugated antihuman IgG, IgA
or IgM at 37°C for 1 h. After the last wash the plates were
developed with 50 µl TMB (tetramethylbenzidine) sub-
strate (medac, Hamburg, Germany) for 30 min. at 37°C.
The reaction was stopped by adding 100 µl of 1 M HCl.
The plates were read by photometric reading at 450 nm on
a Sunrise reader (TECAN, Austria GmbH). A sample was
considered as positive if the antibody titre increased or
decreased with more than 0.4 in absorbence (OD value).
The Complement fixation test
The CF test was performed by standard procedures as an
in-house method. The antigen for this test was supplied by
The National Bacteriological Laboratory in Stockholm. A
fourfold titer rise or a titer of 128 or higher was considered
to be evidence of actual infection.
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